JP2023093753A5 - - Google Patents

Download PDF

Info

Publication number
JP2023093753A5
JP2023093753A5 JP2023076083A JP2023076083A JP2023093753A5 JP 2023093753 A5 JP2023093753 A5 JP 2023093753A5 JP 2023076083 A JP2023076083 A JP 2023076083A JP 2023076083 A JP2023076083 A JP 2023076083A JP 2023093753 A5 JP2023093753 A5 JP 2023093753A5
Authority
JP
Japan
Prior art keywords
seq
set forth
amino acid
acid sequence
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023076083A
Other languages
English (en)
Japanese (ja)
Other versions
JP7611292B2 (ja
JP2023093753A (ja
Filing date
Publication date
Priority claimed from JP2021206917A external-priority patent/JP2022031969A/ja
Application filed filed Critical
Publication of JP2023093753A publication Critical patent/JP2023093753A/ja
Publication of JP2023093753A5 publication Critical patent/JP2023093753A5/ja
Priority to JP2024088870A priority Critical patent/JP2024109952A/ja
Application granted granted Critical
Publication of JP7611292B2 publication Critical patent/JP7611292B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023076083A 2016-11-08 2023-05-02 レプチン受容体をアンタゴナイズする抗原結合性タンパク質 Active JP7611292B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024088870A JP2024109952A (ja) 2016-11-08 2024-05-31 レプチン受容体をアンタゴナイズする抗原結合性タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662419062P 2016-11-08 2016-11-08
US62/419,062 2016-11-08
JP2021206917A JP2022031969A (ja) 2016-11-08 2021-12-21 レプチン受容体をアンタゴナイズする抗原結合性タンパク質

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021206917A Division JP2022031969A (ja) 2016-11-08 2021-12-21 レプチン受容体をアンタゴナイズする抗原結合性タンパク質

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024088870A Division JP2024109952A (ja) 2016-11-08 2024-05-31 レプチン受容体をアンタゴナイズする抗原結合性タンパク質

Publications (3)

Publication Number Publication Date
JP2023093753A JP2023093753A (ja) 2023-07-04
JP2023093753A5 true JP2023093753A5 (https=) 2023-10-06
JP7611292B2 JP7611292B2 (ja) 2025-01-09

Family

ID=60409473

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019523865A Active JP7042816B2 (ja) 2016-11-08 2017-11-08 レプチン受容体をアンタゴナイズする抗原結合性タンパク質
JP2021206917A Pending JP2022031969A (ja) 2016-11-08 2021-12-21 レプチン受容体をアンタゴナイズする抗原結合性タンパク質
JP2023076083A Active JP7611292B2 (ja) 2016-11-08 2023-05-02 レプチン受容体をアンタゴナイズする抗原結合性タンパク質
JP2024088870A Pending JP2024109952A (ja) 2016-11-08 2024-05-31 レプチン受容体をアンタゴナイズする抗原結合性タンパク質

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2019523865A Active JP7042816B2 (ja) 2016-11-08 2017-11-08 レプチン受容体をアンタゴナイズする抗原結合性タンパク質
JP2021206917A Pending JP2022031969A (ja) 2016-11-08 2021-12-21 レプチン受容体をアンタゴナイズする抗原結合性タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024088870A Pending JP2024109952A (ja) 2016-11-08 2024-05-31 レプチン受容体をアンタゴナイズする抗原結合性タンパク質

Country Status (29)

Country Link
US (3) US10550192B2 (https=)
EP (2) EP4613772A3 (https=)
JP (4) JP7042816B2 (https=)
KR (1) KR102563568B1 (https=)
CN (1) CN110167965A (https=)
AU (2) AU2017359439B2 (https=)
CA (1) CA3043365A1 (https=)
CL (3) CL2019001263A1 (https=)
CO (1) CO2019004672A2 (https=)
DK (1) DK3538554T3 (https=)
EA (1) EA201991075A1 (https=)
ES (1) ES3040144T3 (https=)
FI (1) FI3538554T3 (https=)
HR (1) HRP20251165T1 (https=)
HU (1) HUE073276T2 (https=)
IL (2) IL266426B (https=)
LT (1) LT3538554T (https=)
MA (1) MA45801B1 (https=)
MX (2) MX2019005397A (https=)
MY (2) MY203682A (https=)
PH (1) PH12019500988A1 (https=)
PL (1) PL3538554T3 (https=)
PT (1) PT3538554T (https=)
RS (1) RS67214B1 (https=)
SG (1) SG10201913470SA (https=)
SI (1) SI3538554T1 (https=)
SM (1) SMT202500327T1 (https=)
UA (1) UA127678C2 (https=)
WO (1) WO2018089532A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
LT3538554T (lt) 2016-11-08 2025-10-10 Antigeną surišantys baltymai, antagonizuojantys leptino receptorius
SG11202005146VA (en) 2017-12-18 2020-06-29 Regeneron Pharma Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
PT3773713T (pt) 2018-04-06 2025-07-29 Regeneron Pharma Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia
WO2020016160A1 (en) * 2018-07-16 2020-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat neurological diseases
KR20210104744A (ko) * 2018-12-18 2021-08-25 리제너론 파마슈티칼스 인코포레이티드 렙틴 수용체, gdf8 및 액티빈 a에 대한 길항제를 사용하여 체중 및 제지방 근육량을 향상시키기 위한 조성물 및 방법
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
KR20230069969A (ko) * 2020-09-15 2023-05-19 리제너론 파마슈티칼스 인코포레이티드 통증에 대한 lepr 아고니스트의 사용
CN118436632B (zh) * 2024-07-05 2024-08-30 四川大学华西第二医院 Teriflunomide在制备预防和/或治疗原发性纤毛不动综合征的药物中的用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643748A (en) 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor
US6451523B1 (en) 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
US5856098A (en) 1994-09-14 1999-01-05 Progenitor, Inc. Detection of a leptin receptor variant
US5912123A (en) 1994-09-14 1999-06-15 Progenitor, Inc. Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology
US6977240B1 (en) * 1995-11-27 2005-12-20 Millenium Pharmaceuticals, Inc. Methods of using the OB receptor antibodies to treat bodyweight disorders
US6482927B1 (en) 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
US20050019325A1 (en) * 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
AU721129B2 (en) 1996-01-08 2000-06-22 Genentech Inc. WSX receptor and ligands
AU2476301A (en) 1996-01-16 2001-05-24 Rockefeller University, The DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof
US7063958B1 (en) 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
AU1833197A (en) 1996-01-18 1997-08-11 Progenitor, Inc. Detection of a leptin receptor variant and methods for regulating obesity
WO1997027286A1 (en) 1996-01-23 1997-07-31 Progenitor, Inc. Methods for using the obese gene and its gene product to stimulate hematopoietic development
US7067472B1 (en) 1996-06-04 2006-06-27 The Scripps Research Institute Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
US5965521A (en) 1997-02-25 1999-10-12 Eli Lilly Company Pulsatile delivery of leptin receptor ligands
IL120733A0 (en) 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
AU767068B2 (en) 1999-06-11 2003-10-30 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
US20040253242A1 (en) 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
FR2852397B1 (fr) 2003-03-10 2005-04-29 Utilisation des genes leprotl 1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal.
ES2289235T3 (es) * 2003-08-21 2008-02-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Nuevo antagonista de leptina.
DE10353593A1 (de) * 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
US8969291B2 (en) 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
US7863240B2 (en) 2004-10-08 2011-01-04 Enzo Therapeutics, Inc. Methods and uses of leptin in hepatocellular carcinoma
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
US7307142B2 (en) * 2004-11-26 2007-12-11 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Leptin antagonists
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
GB0715216D0 (en) 2007-08-03 2007-09-12 Asterion Ltd Leptin
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
KR20130118941A (ko) 2011-02-10 2013-10-30 로슈 글리카트 아게 면역치료법
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
PL3366705T3 (pl) 2012-09-12 2023-09-18 Genzyme Corporation FC zawierające polipeptydy o zmienionej glikozylacji i zmniejszonej funkcji efektorowej
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
MY178882A (en) * 2013-02-20 2020-10-21 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
US20170051062A1 (en) 2014-02-18 2017-02-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
LT3538554T (lt) 2016-11-08 2025-10-10 Antigeną surišantys baltymai, antagonizuojantys leptino receptorius

Similar Documents

Publication Publication Date Title
JP2023093753A5 (https=)
JP2024038003A5 (https=)
JP2022106952A5 (https=)
JP2024109678A5 (https=)
JP2022177090A5 (https=)
JP2025065427A5 (https=)
JP2022191383A5 (https=)
JP2022534135A5 (https=)
JP2022523442A5 (https=)
JP2025131696A5 (https=)
RU2012112829A (ru) Анти-gitr-антитела
JP2024024114A5 (https=)
JP2025067915A5 (https=)
RU2014147773A (ru) Человеческие антитела с высокой аффинностью к рецепторам il-4 человека
RU2020130795A (ru) Нейтрализующие антитела к env вич-1 и их применение
RU2011105062A (ru) Нейтрализующие антитела против вируса гриппа а и их использование
JP2018536393A5 (https=)
JP2024531409A5 (https=)
JP2011527899A5 (https=)
CN110869390A (zh) 抗pd-l1抗体及其用途
JP2021500916A5 (https=)
JP2023545182A5 (https=)
JP2020511946A5 (https=)
JP2023545183A5 (https=)
JP2024540148A5 (https=)